Sort   by:  
 Page size 
ProteomicsTemporally-resolved proteomic profiling of mouse pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by progressive matrix deposition and fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrix proteome (matrisome) of the highly-metastatic KPC and poorly-metastatic KPflC mouse...
ORGANISM(S): Mus musculus (Mouse) 
2024-08-10 | PXD045830 | Pride
Cancer Pancreas Extracellular matrix 
ProteomicsProteomic analysis Carcinoma associated fibroblasts (CAFs) following genetic manipulation of NID2 expression
Proteomic anlaysis was performed on CAF GFP-1 KRAB, CAF B500 NID2 KRAB and CAF C500 NID2 KRAB cell lines
ORGANISM(S): Homo sapiens (Human) 
2024-08-10 | PXD050045 | Pride
Carcinoma associated fibroblasts Nid2 
UnknownStudy of the doubly charmed tetraquark [Formula: see text].
Quantum chromodynamics, the theory of the strong force, describes interactions of coloured quarks and gluons and the formation of hadronic matter. Conventional hadronic matter consists of baryons and mesons made of three quarks and quark-antiquark pairs, respectively. Particles with an alternative q...
S-EPMC9203551 | biostudies-literature
Unknown20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Background

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side e...
S-EPMC5734609 | biostudies-literature
UnknownTemporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by increasing fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrisome of the highly metastatic KPC (Pdx1-Cre, LSL-KrasG12D/+, LSL-Trp53R172H...
S-EPMC11221519 | biostudies-literature
UnknownImatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Background

Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and e...
S-EPMC8494464 | biostudies-literature
UnknownSafety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination or by repeated infusions of bnAbs. In this study, we administered a recombinant bicistronic adeno-associated viru...
S-EPMC9876739 | biostudies-literature
UnknownAssociation of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19.

Objectives

To determine the association of prior use of renin-angiotensin-aldosterone system inhibitors (RAASIs) with mortality and outcomes in hospitalized patients with COVID-19.

Design

Retrospective observational study.

Setting

Multicenter, international COVID-19 registry.
S-EPMC9469914 | biostudies-literature
UnknownLow-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved β-cell function and reduced HbA1c for 1 year in new-onset type 1 diabet...
S-EPMC6610026 | biostudies-literature
UnknownLow-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

Background

New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed.

Methods

We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antim...
S-EPMC9806693 | biostudies-literature
Sort   by:  
 Page size